Search clinical trials for: PF 05212389 or placebo

Total 1168 results

Pfizer

Completed

A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects

Healthy

United States
Pfizer

Completed

Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

A Phase 1 Study To Evaluate Tolerability, Safety, And Pharmacokinetics Of Topical PF-06263276 In Healthy Subjects

Healthy

Belgium
Pfizer

Completed

Safety And Tolerability Study Of BID Titration Scheme With PF-05089771

Healthy

United States
Pfizer

Completed

Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects

Healthy

United States
Pfizer

Completed

A Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Multiple Oral Doses Of PF-04895162

Healthy

United States
Pfizer

Completed

Multiple Oral Dose Safety, Tolerability And Pharmacokinetic Study Of PF-04287881 In Healthy Adult Subjects

Respiratory Tract Infections

United States
Taisho Pharmaceutical Co., Ltd.

Completed

Multiple Dose Safety Study of PF-04802540 in Healthy Volunteers

Healthy

Singapore
Taisho Pharmaceutical Co., Ltd.

Completed

Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia

Schizophrenia

United States
Pfizer

Terminated

A Phase I, Multiple Dose Study of PF-04447943 in Healthy Elderly Volunteers

Healthy | Elderly

United States
Biogen

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants

Healthy Volunteers

United States
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

Attention Deficit Hyperactivity Disorder

United States
Pfizer

Terminated

Multiple Dose Study in Healthy Volunteers to Assess Safety, Pharmacokinetics and Pharmacodynamics of PF 03882845

Healthy Volunteers

United States
Pfizer

Completed

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

Crohn's Disease

United States, Spain, Lebanon, Australia, Russian Federation, Korea, Republic of, Tunisia, Italy, Poland, Belgium, Austria, Germany, Saudi Arabia, Czechia, Hungary, Switzerland, Turkey, Slovakia, Ukraine, Georgia, Bosnia and Herzegovina and more
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers

Healthy

United States
Pfizer

Completed

A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women

Endometriosis

United States, Belgium
Pfizer

Completed

A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease

Respiratory Tract Diseases | Lung Diseases | Pulmonary Disease, Chronic Obstructive | COPD | Chronic Obstructive Airway Disease

Germany
Biogen

Completed

A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) (TALLY)

Cognitive Impairment Associated With Schizophrenia

Spain, United States, Germany, Japan, United Kingdom
Pfizer

Completed

Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers

Healthy | Sleep

United States
Pfizer

Completed

Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients

Colitis, Ulcerative

Canada, United States, France, Netherlands, Germany, Spain, Austria, Hungary, Bulgaria, Poland, Romania
Pfizer

Completed

6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria

Diabetic Nephropathy

Canada
Pfizer

Terminated

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

Healthy | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Primary Immune Thrombocytopenia

Spain, United States, Belgium, United Kingdom, New Zealand
Pfizer

Completed

First In Human Study Of Increasing Oral Doses Of PF-04634817

Healthy

United States
Pfizer

Completed

PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-2b/3)

Alopecia Areata

China, United States, Spain, Korea, Republic of, Taiwan, Canada, Australia, Germany, Czechia, Poland, Hungary, Japan, United Kingdom, Argentina, Chile, Colombia, Mexico, Russian Federation
Wyeth is now a wholly owned subsidiary of Pfizer
Pfizer

Completed

Study Evaluating The Coadministration of Begacestat And Donepezil

Healthy Subjects

United States
Samjin Pharmaceutical Co., Ltd.

Completed

A Phase 1 Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers

Healthy

Korea, Republic of
Pfizer

Completed

A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Of PF-04447943 When Administered With Donepezil To Healthy Volunteer Subjects

Healthy

Singapore
Pfizer
Trans Tech Pharmaceuticals

Completed

A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

Alzheimer Disease

United States
Pfizer

Withdrawn

A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis

Ulcerative Colitis

United States
Pfizer

Terminated

Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

United States, Japan
Pfizer

Terminated

Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06687234

Healthy

Belgium
Pfizer

Withdrawn

A Study To Assess The Duration Of Action Of PF-03526299 In Asthmatic Subjects Following Allergen Challenge

Asthma
Pfizer

Terminated

A Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers

Sleep | Healthy Volunteers

United States
Pfizer

Recruiting

A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV

Respiratory Syncytial Virus Infections

United States, Israel, Japan, Korea, Republic of, South Africa, Argentina, Canada
Shire

Terminated

Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307) (CARMEN CD 307)

Crohn's Disease

Spain, United States, Korea, Republic of, Australia, Romania, Hungary, Israel, Italy, Croatia, Belgium, Bulgaria, Germany, Poland, Portugal, Argentina, United Kingdom, Greece, New Zealand, Austria, Bosnia and Herzegovina, Colombia, Eston... and more
Shire

Completed

A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis (TURANDOT)

Ulcerative Colitis

United States, France, Spain, Canada, Korea, Republic of, Australia, Germany, New Zealand, Serbia, Belgium, Czechia, Poland, Hungary, Austria, Bulgaria, Israel, Italy, Netherlands, South Africa, Russian Federation, Slovakia
Pfizer

Terminated

A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model (POM)

Healthy

United States
Pfizer

Completed

Multiple Dose Escalation Trial Of PF-04308515 In Healthy Volunteers

Healthy

United States
Pfizer

Completed

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Korea, Republic of, Canada, United States, Australia, United Kingdom, Belgium
Pfizer

Terminated

Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

Advanced Cancer

Italy, United States, Canada, Spain
Yale University
National Institute on Drug Abuse (NIDA); Medical University of South Carolina; Johns Hopkins University and other collaborators

Completed

Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD) (FAAH-I MULTI)

Cannabis Use Disorder

United States
Pfizer

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-06842874 in Healthy Participants

Healthy Participants

United States
Shire

Terminated

Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305) (CARMEN CD 305)

Crohn's Disease

United States, Australia, Romania, Israel, Italy, Croatia, South Africa, Germany, Poland, United Kingdom, Austria, Japan, Lithuania, Netherlands, Russian Federation, Serbia
Pfizer

Completed

Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females

Glucose Metabolism Disorders | Metabolic Diseases | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases

United States
Hospital Ambroise Paré Paris

Completed

Comparison of the Efficacy of rTMS and tDCS of the Motor Cortex in Patients With Chronic Neuropathic Pain

Lumbar Radiculopathy

France
Pfizer

Completed

A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

Non-Alcoholic Fatty Liver Disease (NAFLD)

United States
Pfizer

Completed

Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations

Healthy Participants

United States
Pfizer

Completed

12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin

Diabetes Mellitus, Type 2

United States, Colombia, Spain, Germany, Sweden, Italy
Pfizer

Active, not recruiting

A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection

Eczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, Unspecified

United States, Canada, Czechia, Poland
Pfizer

Terminated

A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)

Dilated Cardiomyopathy | Lamin A/C Gene Mutation

United States, Spain, Canada, Belgium, Italy, Argentina, Mexico, Netherlands, Norway, United Kingdom

3

Subscribe